Characterization of real‐world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center

Abstract

Abstract Objectives We conducted this retrospective study to characterize the change in chronic lymphocytic leukemia (CLL) treatment patterns between 2005 and 2019, to understand the treatment sequencing across the course of the disease, and to investigate how targeted agents and prognostic testing were implemented into the patient care. Methods This study included adult patients with CLL treated at the Hospital District of Southwest Finland during the study period. Data were collected from the Turku University Hospital data lake. Results In total, 122 and 60 patients received first‐ and second‐line treatments for CLL, respectively. The shift from conventional chemoimmunotherapy to targeted treatments in recent years (2014–2019) was observed. The median overall survival times were not reached in patients treated with targeted agents compared to conventional standard treatments in first‐ and second‐line settings and improved toward the end of the study period. Prognostic testing increased during the study follow‐up and patients with unmutated immunoglobulin heavy‐chain variable showed significantly poorer overall survival and time‐to‐next‐treatment outcomes than patients with mutated immunoglobulin heavy‐chain variable. Conclusions This real‐world study implicated added value of targeted chemo‐free therapies as reported in randomized clinical trials, and highlighted the necessity of prognostic testing in order to improve treatment selection and patient outcomes.

Keywords

• chemoimmunotherapy
• chronic lymphocytic leukemia
• IGHV
• survival
• targeted therapy